Wellington Management Group LLP Buys 16,096 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Wellington Management Group LLP increased its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,033,743 shares of the biopharmaceutical company's stock after purchasing an additional 16,096 shares during the period. Wellington Management Group LLP owned approximately 0.97% of Intra-Cellular Therapies worth $86,338,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. GAMMA Investing LLC boosted its holdings in Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after acquiring an additional 240 shares during the period. Venturi Wealth Management LLC bought a new stake in Intra-Cellular Therapies during the fourth quarter valued at about $96,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Intra-Cellular Therapies during the third quarter valued at about $97,000. Quarry LP raised its position in Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock worth $132,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Barlow Wealth Partners Inc. acquired a new position in Intra-Cellular Therapies in the fourth quarter worth about $184,000. 92.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $132.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Piper Sandler reaffirmed a "neutral" rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and raised their price objective for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Needham & Company LLC reaffirmed a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Finally, Baird R W cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Eleven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Intra-Cellular Therapies presently has an average rating of "Hold" and an average price target of $106.23.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ:ITCI remained flat at $131.87 during midday trading on Thursday. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.98. The company's 50 day simple moving average is $130.10 and its 200 day simple moving average is $103.37. The firm has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. As a group, research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.